
News|Articles|April 25, 2024
Shingrix Effective Against Shingles for up to 11 Years Post-Vaccination: Daily Dose
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
Last week, we reported on findings from a long-term follow-up clinical trial that examined the efficacy, safety, and immunogenicity of Shingrix (Recombinant Zoster Vaccine or RZV, GSK) in adults aged 50 years and older.
The study
The ZOSTER-049 study is an extension from 2 phase 3 randomized clinical trials, ZOE-50 and ZOE-70. ZOSTER-049 evaluated the efficacy, safety, and immunogenicity of RZV in adults aged 50 years and older at time of vaccination, for 6 additional years after the ZOE-50 and ZOE-70 studies were completed, and up to approximately 11 years of follow-up.
Over 7000 adults from 18 countries across 5 continents were included in the ZOSTER-049 trial, with vaccine recipients compared to historical controls.
The findings
The final study data showed 79.7% vaccine efficacy (VE) among participants aged 50 years and older cumulatively between 6 to 11 years after vaccination (95% CI 73.7–84.6). Also, RZV was 82% effective in participants at year 11 (95% CI 63.0–92.2), showing VE remains high in each year following vaccination.
Among participants aged 70 years and older, VE was 73.1% from 6 to 11 years after vaccination (95% CI 62.9-80.9), demonstrating high VE rates across all age groups.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Pfizer-BioNTech XFG-Adapted COVID-19 Vaccine for 2026-27 Season
2
5 FDA Decisions for Primary Care to Know from August 2026
3
Diagnosing PMOS in Adolescents: Criteria, Ultrasound Limits, and Red Flags
4
Agitation Associated with Dementia Due to Alzheimer’s Disease: How Common Is It, and How Does It Present?
5























































































































































